Intra-Cellular Therapies Reports First Quarter 2016 Financial Results and Provides Corporate Update

http://ir.intracellulartherapies.com/releasedetail.cfm?ReleaseID=967794

Clinical conduct in ITI-007-302, the second Phase 3 clinical trial of ITI-007 in schizophrenia, is progressing well. Patient enrollment is expected to be completed in the second quarter of 2016.

So the clinical trial will take place in 2017. Hurry up!!

4 Likes

The current Phase 3 trial for sz is happening now. It will end in 2016, in fact first data collection is scheduled soon, with trial ending planned in August 2016.

Current Phase 3 trial for schizophrenia

I hope they can file an application for sz based on this trial.

The trial for bipolar is scheduled to end in December 2017.

1 Like

That news was hot off the press. It says enrollment will be completed for the 2nd phase 3 trial in the 2nd quarter of this year. So I suppose enrollment is technically part of the phase 3 trial.

Yes, enrollment in current sz trial is scheduled to stop accepting new patients soon, I believe.

1 Like

I’d actually misread the original quote, and thought it said 4th quarter, so that’s why I thought 2017 would be the start date.